Danaher Corporation $DHR Shares Bought by Unisphere Establishment

Unisphere Establishment grew its stake in shares of Danaher Corporation (NYSE:DHR) by 12.3% in the 1st quarter, Holdings Channel reports. The firm owned 639,000 shares of the conglomerate’s stock after acquiring an additional 70,000 shares during the quarter. Danaher comprises approximately 1.0% of Unisphere Establishment’s holdings, making the stock its 24th biggest position. Unisphere Establishment’s holdings in Danaher were worth $121,154,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp boosted its position in Danaher by 1.7% during the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares during the period. Capital International Investors grew its stake in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after buying an additional 1,487,768 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Danaher by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after buying an additional 1,334,221 shares during the period. Wellington Management Group LLP increased its position in Danaher by 11.2% in the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after buying an additional 1,517,904 shares during the period. Finally, Norges Bank bought a new stake in Danaher in the fourth quarter valued at $2,177,106,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Guggenheim lowered their price target on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. Citigroup assumed coverage on Danaher in a research report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price for the company. Barclays cut their price target on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Finally, TD Cowen cut their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $228.91.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Danaher Stock Down 0.3%

Shares of Danaher stock opened at $191.87 on Friday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a market cap of $134.88 billion, a P/E ratio of 34.08, a P/E/G ratio of 2.40 and a beta of 0.79. The company has a current ratio of 1.65, a quick ratio of 1.52 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $185.64 and a 200 day moving average price of $197.04.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.77 EPS. As a group, analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is currently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.